Read by QxMD icon Read


shared collection
5 papers 0 to 25 followers
Antonella Tufano, Walter Ageno, Pierpaolo Di Micco, Alferio Niglio, Vladimir Rosa, Aitor Ballaz, Andrei Braester, Carmen Mª Rubio, Virginia Isern, Egidio Imbalzano, Manuel Monreal
INTRODUCTION: Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. METHODS: We used the RIETE (Registro Informatizado Enfermedad Trombo Embólica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT...
February 27, 2018: Thrombosis Research
Jessica Marquez, John C Togami, Colton R Dant, Amanda Herrera, Patricia Marshik, Allison E Burnett
Emerging evidence suggests the use of peri-procedural bridging during interruptions in warfarin therapy increases bleed risk without reducing thromboembolic events. We implemented a peri-procedural anticoagulant management risk assessment tool in a single, outpatient anticoagulation clinic within an academic teaching institution. In this retrospective, pre-post observational study, we evaluated adults who required an interruption in warfarin therapy for an invasive procedure. The primary outcome was the proportion of patients who received bridging prior to and following implementation of the tool...
January 30, 2018: Journal of Thrombosis and Thrombolysis
Daniela Poli, Emilia Antonucci, Francesco Dentali, Nicoletta Erba, Sophie Testa, Eros Tiraferri, Gualtiero Palareti
OBJECTIVE: To evaluate the risk of recurrent intracranial hemorrhage (ICH) in patients on vitamin K antagonists (VKAs) after a first episode of ICH. METHODS: The Cerebral Haemorrhage in patients Restarting Oral Anticoagulant Therapy (CHIRONE) Study collected data of patients eligible for the study from the database of 27 centers affiliated with the Italian Federation of Anticoagulation Clinics. RESULTS: We enrolled 267 patients (163 male, median age 73...
March 25, 2014: Neurology
Lori-Ann Linkins
Vitamin K antagonists are widely used for the prevention of stroke due to atrial fibrillation, treatment and secondary prevention of venous thromboembolism, prevention of valvular thromboembolism in patients with prosthetic heart valves, and secondary prevention of acute myocardial infarction. The most common adverse event experienced by patients receiving anticoagulant therapy is major bleeding. The incidence of major bleeding in patients receiving long-term anticoagulation with a vitamin K antagonist in contemporary studies is 1-3% per year...
May 2013: Blood Reviews
John G Kelton, Donald M Arnold, Shannon M Bates
No abstract text is available yet for this article.
February 21, 2013: New England Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"